Evaluation in usual practice of the bevacizumab-FOLFIRI combination for the first-line treatment of patients with unresectable metastatic colorectal cancer treated in 2006: focus on resected patients and oncogeriatrics: AVASTIN OUEST cohort of the Observatory of Cancer of the Brittany and Pays de la Loire Areas (Observatoire dédié au Cancer Bretagne / Pays de la Loire).

作者: P. Leynia , H. Desclos , J. F. Ramée , H. Senellart , R. Faroux

DOI: 10.1007/S10269-014-2391-1

关键词:

摘要: En 2006, bevacizumab-FOLFIRI represente la therapie ciblee administrable des premiere ligne chez les patients porteurs d’un cancer colorectal metastatique non operable. Une serie homogene de 111 colliges en region Bretagne et Pays Loire ayant recu du bevacizumab- FOLFIRI 2006 revele resultats suivants: 51 reponses, 29 stabilites, 21 progressions 10 toxicites avant evaluation. La mediane survie globale (OS) est 25,1 mois sans progression (PFS) 10,2 mois. Dans le cas d’une chirurgie secondaire, l’OS median triple 18,8 reseques versus 59,2 ceux reseques. comparant sujets âges plus moins 70 ans, aucune difference n’a ete mise evidence termes benefice ou risque. Bevacizumab-FOLFIRI pourrait etre administre pratique courante personnes âgees sous couvert evaluation geriatrique approche multidisciplinaire.

参考文章(26)
Françoise Grudé, Réjane Bessard, Hugues Bourgeois, Jean-Yves Douillard, Erik Gamelin, Jean-Philippe Metges, Christian Riché, Anne-Marie Vidal, Optimisation du bon usage et maîtrise des coûts des médicaments anticancéreux : expérience de l’Observatoire dédié au Cancer Bretagne – Pays-de-la-Loire Bulletin Du Cancer. ,vol. 100, pp. 271- 282 ,(2013) , 10.1684/BDC.2013.1715
Volker Heinemann, Ludwig Fischer von Weikersthal, Thomas Decker, Alexander Kiani, Ursula Vehling-Kaiser, Salah-Eddin Al-Batran, Tobias Heintges, Juergen Lerchenmueller, Christoph Kahl, Gernot Seipelt, Frank Kullmann, Martina Stauch, Werner Scheithauer, Joerg Hielscher, Michael Scholz, Sebastian Mueller, Britta Schaefer, Dominik Paul Modest, Andreas Jung, Sebastian Stintzing, Randomized comparison of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment of KRAS-wildtype metastatic colorectal cancer: German AIO study KRK-0306 (FIRE-3). Journal of Clinical Oncology. ,vol. 31, ,(2013) , 10.1200/JCO.2013.31.15_SUPPL.LBA3506
Daniel J. Sargent, Richard M. Goldberg, Stacy D. Jacobson, John S. Macdonald, Roberto Labianca, Daniel G. Haller, Lois E. Shepherd, Jean François Seitz, Guido Francini, A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. The New England Journal of Medicine. ,vol. 345, pp. 1091- 1097 ,(2001) , 10.1056/NEJMOA010957
Carsten Bokemeyer, Eric Van Cutsem, Philippe Rougier, Fortunato Ciardiello, Steffen Heeger, Michael Schlichting, Ilhan Celik, Claus-Henning Köhne, Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials. European Journal of Cancer. ,vol. 48, pp. 1466- 1475 ,(2012) , 10.1016/J.EJCA.2012.02.057
Thierry Delaunoit, Richard M. Goldberg, Daniel J. Sargent, Roscoe F. Morton, Charles S. Fuchs, Brian P. Findlay, Sachdev P. Thomas, Muhammad Salim, Paul L. Schaefer, Philip J. Stella, Erin Green, James A. Mailliard, Mortality associated with daily bolus 5-fluorouracil/leucovorin administered in combination with either irinotecan or oxaliplatin: results from Intergroup Trial N9741. Cancer. ,vol. 101, pp. 2170- 2176 ,(2004) , 10.1002/CNCR.20594
Jean-Yves Douillard, Kelly S Oliner, Salvatore Siena, Josep Tabernero, Ronald Burkes, Mario Barugel, Yves Humblet, Gyorgy Bodoky, David Cunningham, Jacek Jassem, Fernando Rivera, Ilona Kocákova, Paul Ruff, Maria Błasińska-Morawiec, Martin Šmakal, Jean Luc Canon, Mark Rother, Richard Williams, Alan Rong, Jeffrey Wiezorek, Roger Sidhu, Scott D Patterson, None, Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer The New England Journal of Medicine. ,vol. 369, pp. 1023- 1034 ,(2013) , 10.1056/NEJMOA1305275
Jean-Yves Douillard, Salvatore Siena, James Cassidy, Josep Tabernero, Ronald Burkes, Mario Barugel, Yves Humblet, György Bodoky, David Cunningham, Jacek Jassem, Fernando Rivera, Ilona Kocákova, Paul Ruff, Maria Błasińska-Morawiec, Martin Šmakal, Jean-Luc Canon, Mark Rother, Kelly S Oliner, Michael Wolf, Jennifer Gansert, None, Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study Journal of Clinical Oncology. ,vol. 28, pp. 4697- 4705 ,(2010) , 10.1200/JCO.2009.27.4860
Fairooz F. Kabbinavar, Herbert I. Hurwitz, Jing Yi, Somnath Sarkar, Oliver Rosen, Addition of Bevacizumab to Fluorouracil-Based First-Line Treatment of Metastatic Colorectal Cancer: Pooled Analysis of Cohorts of Older Patients From Two Randomized Clinical Trials Journal of Clinical Oncology. ,vol. 27, pp. 199- 205 ,(2009) , 10.1200/JCO.2008.17.7931
Axel Grothey, Mary M. Sugrue, David M. Purdie, Wei Dong, Daniel Sargent, Eric Hedrick, Mark Kozloff, Bevacizumab Beyond First Progression Is Associated With Prolonged Overall Survival in Metastatic Colorectal Cancer: Results From a Large Observational Cohort Study (BRiTE) Journal of Clinical Oncology. ,vol. 26, pp. 5326- 5334 ,(2008) , 10.1200/JCO.2008.16.3212
Marc Peeters, Timothy Jay Price, Andrés Cervantes, Alberto F. Sobrero, Michel Ducreux, Yevhen Hotko, Thierry André, Emily Chan, Florian Lordick, Cornelis J.A. Punt, Andrew H. Strickland, Gregory Wilson, Tudor-Eliade Ciuleanu, Laslo Roman, Eric Van Cutsem, Valentina Tzekova, Simon Collins, Kelly S. Oliner, Alan Rong, Jennifer Gansert, Randomized Phase III Study of Panitumumab With Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) Compared With FOLFIRI Alone As Second-Line Treatment in Patients With Metastatic Colorectal Cancer Journal of Clinical Oncology. ,vol. 28, pp. 4706- 4713 ,(2010) , 10.1200/JCO.2009.27.6055